



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

SEP 29 2009

Re: Mozobil  
Docket No. FDA-2009-E-0164

The Honorable David J. Kappos  
Under Secretary of Commerce for Intellectual Property  
Director of the United States Patent and Trademark Office  
Mail Stop Hatch-Waxman PTE  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the application for patent term extension for U.S. Patent No. 5,583,131 filed by Genzyme Corporation, under 35 U.S.C. § 156. The human drug product claimed by the patent is Mozobil (plerixafor), which was assigned new drug application (NDA) No. 22-311.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1).

The NDA was approved on December 15, 2008, which makes the submission of the patent term extension application on February 6, 2009, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in cursive script, reading "Jane A. Axelrad", is written in black ink.

Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

• Kappos - Mozobil  
Patent No. 5,583,131  
Page 2

cc: Charles E. Van Horn  
Finnegan, Henderson, Farabox, Garrett & Dunnerk LLP  
901 New York Avenue, N.W.  
Washington, DC 20001-4413